We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

50 hedge funds and large institutions have $49.3M invested in Catalyst Pharmaceutical in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more capital invested

Capital invested by funds: $25M → $49.3M (+$24.3M)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

1.76% more ownership

Funds ownership: 28.74% → 30.5% (+1.8%)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

7% less funds holding

Funds holding: 54 → 50 (-4)

Holders
50
Holders Change
-4
Holders Change %
-7.41%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
10
Closed
10
Calls
$412K
Puts
–
Net Calls
+$412K
Net Calls Change
+$412K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$3.39M
2
CS
Candriam SCA
Luxembourg
+$764K
3
BlackRock
BlackRock
New York
+$704K
4
Renaissance Technologies
Renaissance Technologies
New York
+$487K
5
DMK
David M. Knott
+$362K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.78M
2
KCM
Kingdon Capital Management
New York
-$794K
3
TCM
Tanaka Capital Management
New York
-$443K
4
Millennium Management
Millennium Management
New York
-$331K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$63K

CPRX Hedge Fund Activity: Q1 2017 in Review

50 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2017, worth a combined $49.3M — up 97% from $25M a quarter earlier.

Fund positioning in CPRX was balanced in Q1 2017: 10 funds opened new positions, 10 closed out, 13 added to existing stakes and 10 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $3.39M. The largest seller was Point72 Asset Management, cutting an estimated $1.78M.

  • 50 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2017, down from 54 in Q4 2016.
  • Funds reported $49.3M of Catalyst Pharmaceutical stock for Q1 2017, up 97% quarter-over-quarter.
  • 10 funds opened new Catalyst Pharmaceutical positions in Q1 2017 and 10 closed out, a net change of 0 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2017 was Avoro Capital Advisors, an estimated $3.39M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2017 was Point72 Asset Management, an estimated $1.78M sold.

Based on aggregated 13F filings for Q1 2017.